Medication-assisted treatment (MAT) combines the use of FDA-approved medications — methadone, buprenorphine, and naltrexone — with behavioral therapy and is recognized as the most effective treatment method for lasting recovery from opioid use disorder. The widespread adoption of MAT is hampered by a number of systemic barriers. The most notable difficulty is the significant shortage of authorized prescribers, which results from a combination of regulatory constraints and reimbursement limitations.

Evidence shows that using telehealth to deliver MAT is an effective alternative to in-person treatment and is growing in acceptance and demand across the US. While regulatory and reimbursement challenges remain, the crushing weight of the opioid epidemic is creating momentum across the country to remove these barriers. This brief provides an overview of the developing but nascent landscape of organizations offering telehealth MAT.

Telepsychiatry Providers Adding MAT Services

Addiction or MAT-Specific Telehealth Providers

Readers should note this landscape overview is not intended to be exhaustive, nor is it an endorsement of the companies included in it. Finally, because solutions landscapes can evolve quickly, this report may not fully reflect the current market.